Axonics (Axonics) ROCE % : 2.83% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Axonics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Axonics's annualized ROCE % for the quarter that ended in Dec. 2023 was 2.83%.

Axonics ROCE % Historical Data

The historical data trend for Axonics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics ROCE % Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.53

-21.03

-17.58

-10.74

-0.74

Axonics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-0.31	-8.44	2.62	2.31	2.83

Axonics ROCE % Calculation

Axonics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.712	/	( ( (659.353 - 65.247)	+	(719.923 - 45.816) )	/ 2 )
	=	-4.712	/	( (594.106	+	674.107)	/ 2 )
	=	-4.712	/	634.1065
	=	-0.74 %

Axonics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	18.384	/	( ( (660.747 - 35.593)	+	(719.923 - 45.816) )	/ 2 )
	=	18.384	/	( ( 625.154	+	674.107 )	/ 2 )
	=	18.384	/	649.6305
	=	2.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Axonics (NAS:AXNX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Axonics ROCE % Related Terms

Thank you for viewing the detailed overview of Axonics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (Axonics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0I3:Germany 0I3:Germany

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Executives

Karen Noblett	officer: Chief Medical Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese	officer: Chief Financial Officer	15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen	officer: See Remarks	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr	officer: Chief Commercial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama	officer: Chief Operating Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock	officer: Chief Marketing Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen	director, officer: Chief Executive Officer
Esteban Lopez	director	6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski	director	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara	director	C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms	director, 10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera	10 percent owner	374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski	director, 10 percent owner	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920